These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 31042572)

  • 1. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
    Stanek LM; Bu J; Shihabuddin LS
    Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
    Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
    Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
    Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease.
    Meunier C; Merienne N; Jollé C; Déglon N; Pellerin L
    Glia; 2016 Nov; 64(11):1841-56. PubMed ID: 27442486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
    Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
    Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
    Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
    Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
    Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
    J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astrocytic contributions to Huntington's disease pathophysiology.
    Khakh BS; Goldman SA
    Ann N Y Acad Sci; 2023 Apr; 1522(1):42-59. PubMed ID: 36864567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease.
    Oliveira AO; Osmand A; Outeiro TF; Muchowski PJ; Finkbeiner S
    Hum Mol Genet; 2016 May; 25(9):1677-89. PubMed ID: 26920069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity.
    Lemarié FL; Caron NS; Sanders SS; Schmidt ME; Nguyen YTN; Ko S; Xu X; Pouladi MA; Martin DDO; Hayden MR
    Neurobiol Dis; 2021 Oct; 158():105479. PubMed ID: 34390831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors.
    Gangwani MR; Soto JS; Jami-Alahmadi Y; Tiwari S; Kawaguchi R; Wohlschlegel JA; Khakh BS
    Cell Rep; 2023 Jan; 42(1):111953. PubMed ID: 36640336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
    Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
    Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice.
    Jing L; Cheng S; Pan Y; Liu Q; Yang W; Li S; Li XJ
    Mol Neurobiol; 2021 Oct; 58(10):5112-5126. PubMed ID: 34250577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.